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Transcatheter Aortic Valve Replacement*
Martyn Thomas, MDT he PARTNER (Placement of AoRTic TraNs-cathetER Valve) transcatheter aortic valvereplacement (TAVR) trials were pivotal to
the development of TAVR throughout the world.
Whereas TAVR was propagated in Europe by “heart
teams” and the availability of CE-marked TAVR
devices, the Food and Drug Administration in the
United States mandated randomized clinical trials
(RCTs) of TAVR versus medical therapy in inoperable
patients (PARTNER 1B [1]) and TAVR versus surgical
aortic valve replacement in high-risk surgical pa-
tients (PARTNER 1A [2]). Following completion of the
PARTNER randomized trials, the Food and Drug
Administration allowed a nonrandomized continued
access (NRCA) registry including >1,000 patients
including a newer generation transfemoral (TF) deliv-
ery system and greater access to a non-TF (transapical)
vascular access.SEE PAGE 1245The paper by Fearon et al. (3) in this issue of JACC:
Cardiovascular Interventions compares the outcome
of, speciﬁcally, TF TAVR in the PARTNER randomized
trials and TF patients in the NRCA registry. Despite
a change in delivery system, the 23- and 26-mm
Edwards Sapien valves required a 22- or 24-F sheath
throughout both of these studies. The major ﬁnding
of the study was that the 1-year mortality was
signiﬁcantly lower in the NRCA (19% vs. 25.3%,
p ¼ 0.009), and there were also lower rates of major
vascular complications (8% vs. 15.7%, p < 0.0001)
and major bleeding (6.8% vs. 15.3%, p < 0.0001).*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
Dr. Thomas is a consultant to and an advisory board member of Edwards
Lifesciences.Thirty-day complications such as death and stroke
were the same for both theRCTs and theNRCA registry.
It would have been disappointing if the NRCA re-
sults were not better than those of the PARTNER
RCTs. Patients were enrolled into the RCTs between
May 2007 and August 2009, whereas patients were
enrolled into the NRCA between September 2009 and
January 2012. Much has been learned about the TAVR
procedure and patient selection between 2007
and 2009. The procedure duration was signiﬁcantly
shorter in the NRCA patients (117.6 vs. 145.1 min,
p < 0.0001), demonstrating this learning curve. A
better understanding of the procedure is also
reﬂected in the reduction in major vascular compli-
cations and major bleeding in the NRCA patients.
Equally, the patients in the NRCA registry were lower
risk (reﬂected in the STS and Logistic EuroSCORE:
10.86 vs. 11.58, p ¼ 004, and 24.25 vs. 28.14,
p < 0.0001, respectively) because of lower comor-
bidities, and this is the likely reason for the lower 1-
year mortality. Whereas the breakdown of patients
in the RCT patients is clear (58% from the high-risk
patients and 42% from the inoperable patients), this
is not stated for the NRCA patients. It would be
interesting to know whether these percentages have
changed with time.
It is well known that the measurement of risk for
TAVR patients is difﬁcult. Neither the STS or logistic
EuroSCORE are ideal, but these are the scores
currently in use. Although they are poor at estimating
absolute risk, they do categorize risk, that is, high,
intermediate, or low. These risk measures appear to
better estimate risks of mortality at 1 year than
30 days. It is interesting to look at these risk mea-
sures in the PARTNER RCTs, the CoreValve U.S.
Pivotal trials, and the NRCA registry, and assess the
potential impact on 1-year mortality. The ﬁrst trials
performed were PARTNER 1A and 1B. Despite the
patients in 1B being considered inoperable, their risk
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1253values were numerically lower than the high-risk 1A
patients: STS and logistic EuroSCORE were 11.2% and
26.4% versus 11.8% and 29.3%, respectively. However
the clinical judgment of the physicians appears cor-
rect in that the 1-year mortality was 30.7% in the
inoperable patients compared with 24.2% in the high-
risk surgical patients. These measures of risk were
numerically lower in the High Risk and Extreme Risk
CoreValve U.S. Pivotal trials (4,5); STS and logistic
EuroSCORE were 7.3% and 17.6% in the High Risk and
10.3% and 22.7% in the Extreme Risk trials, respec-
tively. The resulting mortalities at 1 year were 14.2%
in the high-risk TAVR patients and 25.5% in the
extreme-risk patients. The NRCA patients appear to
occupy a middle ground with an STS of 10.86 and a
logistic EuroSCORE of 24.25. The resultant 1-year
mortality was lower than the PARTNER trials at
19%. These ﬁgures suggest that one of the strongest
indicators of 1-year survival in TAVR patients
(although not an absolute estimate) is the original
STS and logistic EuroSCORE.
It is interesting to compare the results of the NRCA
registry with recent European registries. The Edwards
Sapien valve (Edwards Lifesciences, Irvine, Califor-
nia) is a ﬁrst-generation TAVR device. In Europe,
there are 1-year systematic registry outcomes data on
the second-generation Sapien (the SOURCE XT reg-
istry using the Sapien XT valve) (6) and similar 30-day
data from the third-generation Sapien 3 European CE
Mark Registry (7). For the TF patients in the SOURCE
XT registry, the 30-day mortality was 4.2% and 1-year
mortality was 15%. The NRCA mortalities of 4.3% at30 days and 19% at 1 year compare favorably with
these results. The 30-day mortality for the TF patients
in the Sapien 3 Registry was very low at 2.1% with a
stroke rate of only 1%. The stroke rate in the NRCA
registry was 3.7%. These data suggest that improved
device design can result in improved 30-day out-
comes, including reduced stroke rates.
Finally, it is interesting to compare the results of
the NRCA registry patients with the surgical aortic
valve replacement patients in the PARTNER 1A trial
and speculate whether these results may be different
if the trial was repeated after centers had gained
more experience. The 1-year mortality of the surgical
arm in the PARTNER 1A trial was 26.8%. The 1-year
mortality of 19% in the NRCA registry would reﬂect
a 29% reduction in mortality compared with this
historical control group. This, of course, is merely
speculation but might suggest that improved results
of TAVR with time and experience would result in a
different result of a high-risk surgical trial, as recently
demonstrated in the CoreValve Pivotal Trial High-
Risk study (4).
Overall, these data suggest that improved patient
selection, advances in device technology, and
increased experience with the TAVR procedure will
result in improved patient outcomes both at 30 days
and at 1 year.
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